Lionel Adès, MD, PhD, Gives an Update on Targeted Therapies for MDS
By Kerri Fitzgerald - Last Updated: November 15, 2022Lionel Adès, MD, PhD, spoke with Blood Cancers Today about the session he presented at the 2022 SOHO Annual Meeting, highlighting three different kinds of targeted therapy that have been developed for MDS.
Advertisement
Post Tags:MDS at SOHO 2022
Advertisement
Related Posts
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
The investigational small molecule enzomenib has received FDA Orphan Drug and Fast Track designations in AML.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.